title: Evidence for distinct dehydrogenase and isomerase sites within a single 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase protein.
abstract: Complementary DNA encoding human 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase (3 beta-HSD) has been expressed in transfected GH4C1 with use of the cytomegalovirus promoter. The activity of the expressed protein clearly shows that both dehydrogenase and isomerase enzymatic activities are present within a single protein. However, such findings do not indicate whether the two activities reside within one or two closely related catalytic sites. With use of [3H]-5-androstenedione, the intermediate compound in dehydroepiandrosterone (DHEA) transformation into 4-androstenedione by 3 beta-HSD, the present study shows that 4MA (N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxamide) and its analogues inhibit DHEA oxidation competitively while they exert a noncompetitive inhibition of the isomerization of 5-androstenedione to 4-androstenedione with an approximately 1000-fold higher Ki value. The present results thus strongly suggest that dehydrogenase and isomerase activities are present at separate sites on the 3 beta-HSD protein. In addition, using 5 alpha-dihydrotestosterone (DHT) and 5 alpha-androstane-3 beta, 17 beta-diol as substrates for dehydrogenase activity only, we have found that dehydrogenase activity is reversibly and competitively inhibited by 4MA. Such data suggest that the irreversible step in the transformation of DHEA to 4-androstenedione is due to a separate site possessing isomerase activity that converts the 5-ene-3-keto to a much more stable 4-ene-3-keto configuration.
authors.affiliation: MRC Group in Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
authors.forename: V
authors.initials: V
authors.lastname: Luu-The
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: de Launoit
authors.forename: M
authors.initials: M
authors.lastname: Dumont
authors.forename: Y
authors.initials: Y
authors.lastname: Lachance
authors.forename: F
authors.initials: F
authors.lastname: Labrie
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D015113:Androstane-3,17-diol / Q000378:metabolism; D001378:Azasteroids / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D002460:Cell Line; D003687:Dehydroepiandrosterone / Q000378:metabolism; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000737:chemistry*; D010920:Placenta / Q000201:enzymology; D011375:Progesterone Reductase / Q000037:antagonists & inhibitors / Q000737:chemistry*; D011487:Protein Conformation; D013251:Steroid Isomerases / Q000037:antagonists & inhibitors / Q000737:chemistry*; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured
chemical_list: C021425:3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase; D000726:Androgen Antagonists; D001378:Azasteroids; D009097:Multienzyme Complexes; D013196:Dihydrotestosterone; D015113:Androstane-3,17-diol; D003687:Dehydroepiandrosterone; C031563:17-N,N-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one; D011375:Progesterone Reductase; D013251:Steroid Isomerases; C009954:trilostane